Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Czeladź

3 clinical trials in Czeladź, Poland. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Czeladź at a glance
3
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

3 trials in Czeladź

Open in trial search

Chronic kidney disease

Recruiting
Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Azd5004
  • Sponsor:AstraZeneca AB

Atrial fibrillation

Not yet recruiting
Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting
Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Regn7508
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Czeladź

What the registry says about research in the country

01 Czeladź
Atrial Fibrillation (AF) Study
The ongoing trial in Czeladź focuses on non‑permanent atrial fibrillation, a common cardiovascular condition. Researchers are testing the investigational drug budiodarone to assess its safety, tolerability, and ability to prevent arrhythmic progression. The study also tracks the occurrence of major adverse cardiac events as key safety endpoints. Safety and tolerability assessment of the investigational therapy Evaluation of efficacy in preventing arrhythmia recurrence Monitoring of treatment‑emergent adverse events Dose escalation to determine optimal dosing With two recruiting studies, one research site, and three investigators, the city is contributing valuable data to improve AF management.
Chronic Kidney Disease and Cardiovascular Outcomes
A parallel study in Czeladź enrolls adults with chronic kidney disease across a range of eGFR and albuminuria levels. The trial compares the novel agent elecoglipron against placebo to evaluate its effect on kidney outcomes. One key measure is a sustained ≥50 % decline in eGFR. The study also monitors progression to end‑stage kidney disease and overall mortality. Assessment of composite renal endpoint Measurement of eGFR trajectory over time Evaluation of incidence of end‑stage kidney disease Analysis of all‑cause mortality impact Both studies are actively recruiting, highlighting the city’s role in advancing cardiovascular‑related therapies for patients with kidney impairment.
Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.